Jean Nicolas Vauthey

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Southwest Oncology Group 0408: Phase II trial of neoadjuvant capecitabine/oxaliplatin/bevacizumab for resectable colorectal metastases in the liver
    Eddie K Abdalla
    Department of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston 77230-1402, USA
    Clin Colorectal Cancer 5:436-9. 2006
  2. ncbi Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases
    Junichi Shindoh
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 30:4566-72. 2012
  3. ncbi Surgical margins during hepatic surgery for colorectal liver metastases: complete resection not millimeters defines outcome
    Timothy M Pawlik
    Department of Surgery, Johns Hopkins Hospital, Maryland, USA
    Ann Surg Oncol 15:677-9. 2008
  4. ncbi Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma
    M M Bilimoria
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 106, Houston, TX 77030, USA
    Arch Surg 136:528-35. 2001
  5. ncbi Pretreatment assessment of hepatocellular carcinoma: expert consensus statement
    Jean Nicolas Vauthey
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    HPB (Oxford) 12:289-99. 2010
  6. ncbi Is extended hepatectomy for hepatobiliary malignancy justified?
    Jean Nicolas Vauthey
    Departments of Surgical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA
    Ann Surg 239:722-30; discussion 730-2. 2004
  7. ncbi Proceedings of the Fifth International Meeting, Hepatocellular Carcinoma: Eastern and Western Experiences Overview of the Conference
    Jean-Nicolas Vauthey
    Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, Texas, USA
    Ann Surg Oncol 15:961. 2008
  8. ncbi Case 57: eosinophilic cholangiopathy
    Jean-Nicolas Vauthey
    Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Box 444, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Radiology 227:107-12. 2003
  9. ncbi Making unresectable hepatic colorectal metastases resectable--does it work?
    Jean Nicolas Vauthey
    Department of Surgery, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Semin Oncol 32:S118-22. 2005
  10. ncbi AHPBA/SSO/SSAT Consensus Conference on hepatic colorectal metastases: rationale and overview of the conference. January 25, 2006
    Jean-Nicolas Vauthey
    Department of Surgical Oncology, Unit 444, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, 77030, USA
    Ann Surg Oncol 13:1259-60. 2006

Detail Information

Publications130 found, 100 shown here

  1. ncbi Southwest Oncology Group 0408: Phase II trial of neoadjuvant capecitabine/oxaliplatin/bevacizumab for resectable colorectal metastases in the liver
    Eddie K Abdalla
    Department of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston 77230-1402, USA
    Clin Colorectal Cancer 5:436-9. 2006
  2. ncbi Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases
    Junichi Shindoh
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 30:4566-72. 2012
    ....
  3. ncbi Surgical margins during hepatic surgery for colorectal liver metastases: complete resection not millimeters defines outcome
    Timothy M Pawlik
    Department of Surgery, Johns Hopkins Hospital, Maryland, USA
    Ann Surg Oncol 15:677-9. 2008
  4. ncbi Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma
    M M Bilimoria
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 106, Houston, TX 77030, USA
    Arch Surg 136:528-35. 2001
    ..A subset of patients can be identified who will survive without recurrence beyond 5 years after hepatic resection for hepatocellular carcinoma (HCC)...
  5. ncbi Pretreatment assessment of hepatocellular carcinoma: expert consensus statement
    Jean Nicolas Vauthey
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    HPB (Oxford) 12:289-99. 2010
    ..Liver resection can be proposed in selected patients with multifocal HCC. Besides tumor extent, surgical resection of HCC may be performed in selected patients with chronic liver disease...
  6. ncbi Is extended hepatectomy for hepatobiliary malignancy justified?
    Jean Nicolas Vauthey
    Departments of Surgical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA
    Ann Surg 239:722-30; discussion 730-2. 2004
    ..Extended hepatectomy may be required to provide the best chance for cure of hepatobiliary malignancies. However, the procedure may be associated with significant morbidity and mortality...
  7. ncbi Proceedings of the Fifth International Meeting, Hepatocellular Carcinoma: Eastern and Western Experiences Overview of the Conference
    Jean-Nicolas Vauthey
    Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, Texas, USA
    Ann Surg Oncol 15:961. 2008
  8. ncbi Case 57: eosinophilic cholangiopathy
    Jean-Nicolas Vauthey
    Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Box 444, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Radiology 227:107-12. 2003
  9. ncbi Making unresectable hepatic colorectal metastases resectable--does it work?
    Jean Nicolas Vauthey
    Department of Surgery, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Semin Oncol 32:S118-22. 2005
    ..Other approaches for patients with bilobar metastases include two-stage hepatic resection and the combined use of resection with radiofrequency ablation...
  10. ncbi AHPBA/SSO/SSAT Consensus Conference on hepatic colorectal metastases: rationale and overview of the conference. January 25, 2006
    Jean-Nicolas Vauthey
    Department of Surgical Oncology, Unit 444, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, 77030, USA
    Ann Surg Oncol 13:1259-60. 2006
  11. ncbi Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases
    Jean Nicolas Vauthey
    Department of Surgical Oncology, Unit 444, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 24:2065-72. 2006
    ..Chemotherapy before resection of hepatic colorectal metastases (CRM) may cause hepatic injury and affect postoperative outcome...
  12. ncbi Simplified staging for hepatocellular carcinoma
    Jean Nicolas Vauthey
    International Cooperative Study Group on Hepatocellular Carcinoma, Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 20:1527-36. 2002
    ..The current American Joint Committee on Cancer (AJCC) staging system for hepatocellular carcinoma (HCC) fails to stratify patients adequately with respect to prognosis...
  13. ncbi Body surface area and body weight predict total liver volume in Western adults
    Jean Nicolas Vauthey
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Liver Transpl 8:233-40. 2002
    ..The new formulas derived from this correlation should contribute to the estimation of TLV before liver transplantation or major hepatic resection...
  14. ncbi Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head
    Douglas B Evans
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 26:3496-502. 2008
    ..We conducted a phase II trial to assess the outcomes of patients who received preoperative gemcitabine-based chemoradiation and pancreaticoduodenectomy (PD) for stage I/II pancreatic adenocarcinoma...
  15. ncbi Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases
    Dipen M Maru
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 34:1287-94. 2010
    ....
  16. ncbi Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation
    Matthew H G Katz
    Department of Surgery, The University of California, Orange, CA, USA
    Ann Surg Oncol 17:1794-801. 2010
    ..We evaluated CA 19-9 as a marker of therapeutic response, completion of therapy, and survival in patients enrolled on two recently reported clinical trials...
  17. ncbi Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma
    Yehuda Z Patt
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:578-86. 2004
    ..The goal of the current study was to evaluate the efficacy and toxicity of capecitabine in patients with nonresectable hepatobiliary carcinoma...
  18. ncbi Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy?
    Antoine Brouquet
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Am Coll Surg 210:934-41. 2010
    ..An increasing number of patients with synchronous colorectal liver metastases (CLM) are candidates for resection. The optimal treatment sequence in these patients has not been defined...
  19. ncbi Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases
    Andreas Andreou
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg 256:642-50. 2012
    ..We hypothesized that metachronous colorectal liver metastases (CLM) have different biology after failure of oxaliplatin (FOLFOX) compared to 5-fluorouracil (5-FU) or no chemotherapy for adjuvant treatment of colorectal cancer (CRC)...
  20. ncbi Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant
    Junichi Shindoh
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
    J Am Coll Surg 216:201-9. 2013
    ..However, the regeneration rate of the FLR after PVE varies among individuals and its clinical significance is unknown...
  21. ncbi Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:2045-53. 2012
    ..By means of this system, we sought to analyze outcomes of patients with resectable anatomy but heterogeneous biology and physiology who were treated with neoadjuvant therapy...
  22. ncbi Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA
    J Gastrointest Surg 16:68-78; discussion 78-9. 2012
    ..To determine the influence of neoadjuvant chemoradiation and standardized dissection of the superior mesenteric artery upon the oncologic outcome of patients with localized pancreatic adenocarcinoma...
  23. ncbi Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
    Antoine Brouquet
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:4484-92. 2011
    ..Patient outcomes following resection of colorectal liver metastases (CLM) after second-line chemotherapy regimen is unknown...
  24. ncbi Transhepatic ipsilateral right portal vein embolization extended to segment IV: improving hypertrophy and resection outcomes with spherical particles and coils
    David C Madoff
    Division of Diagnostic Imaging, Interventional Radiology Section, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 325, Houston, Texas 77030, USA
    J Vasc Interv Radiol 16:215-25. 2005
    ....
  25. ncbi Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases
    Yun Shin Chun
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    JAMA 302:2338-44. 2009
    ....
  26. ncbi Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry
    Yoji Kishi
    Department of Surgical Oncology, Unit 444, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Ann Surg 250:540-8. 2009
    ..Secondary end point was to assess whether preoperative portal vein embolization (PVE) is associated with improved outcome in patients with initial sFLR ≤ 20%...
  27. ncbi I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score
    Ahmed O Kaseb
    Department of Gastrointestinal Medical Oncology, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Oncology 80:373-81. 2011
    ....
  28. ncbi Risk of venous thromboembolism outweighs post-hepatectomy bleeding complications: analysis of 5651 National Surgical Quality Improvement Program patients
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    HPB (Oxford) 14:506-13. 2012
    ..The relationships between extent of hepatectomy, postoperative VTE and bleeding events were evaluated using the National Surgical Quality Improvement Program (NSQIP) database...
  29. ncbi Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    HPB (Oxford) 14:365-72. 2012
    ..Following potentially curative resection at this centre, patients with pancreatic adenocarcinoma (PAC) are routinely enrolled in a programme of clinical and radiographic surveillance. This study sought to evaluate its diagnostic yield...
  30. ncbi Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases
    Yoji Kishi
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 17:2870-6. 2010
    ..We evaluated the association between the duration of preoperative chemotherapy with 5-fluorouracil (5-FU), leucovorin, oxaliplatin (FOLFOX) ± bevacizumab, pathologic response, and hepatotoxicity after hepatic resection for CLM...
  31. ncbi Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases
    Susan B Kesmodel
    Department of Surgical Oncology, Cancer Biology, Biostatistics, and Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 26:5254-60. 2008
    ..We therefore evaluated whether neoadjuvant BV is associated with an increase in postoperative complications in patients undergoing surgery for CRC liver metastases...
  32. ncbi High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome
    Antoine Brouquet
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    J Clin Oncol 29:1083-90. 2011
    ..The impact of complete resection in this well-selected group is controversial...
  33. ncbi Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy?
    Thomas A Aloia
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Am Coll Surg 204:347-55. 2007
    ..This study reexamined the frequency of delayed recovery and assessed other factors associated with adjuvant therapy administration after PD at a high-volume center...
  34. ncbi Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy
    Scott Kopetz
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 27:3677-83. 2009
    ....
  35. ncbi Transhepatic portal vein embolization: anatomy, indications, and technical considerations
    David C Madoff
    Department of Diagnostic Imaging, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 57, Houston, TX 77030 4009, USA
    Radiographics 22:1063-76. 2002
    ..Nevertheless, as hepatobiliary surgeons become more experienced at performing extended hepatic resections, PVE may be requested more frequently...
  36. ncbi Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases
    Dario Ribero
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2761-7. 2007
    ..The current study evaluated the effect of bevacizumab added to fluoropyrimidine-plus-oxaliplatin (5FU/OX) chemotherapy for colorectal liver metastases (CLM) on the pathologic response and nontumorous liver histology...
  37. ncbi Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy
    John T Mullen
    Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Coll Surg 204:854-62; discussion 862-4. 2007
    ..No standard definition of PHI has been established, but one is essential for meaningful comparison of outcomes data across studies...
  38. ncbi Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation
    Jiansheng Wang
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 118:3801-11. 2012
    ..However, the prognostic significance of tumor involvement of the resected vein in patients who received neoadjuvant therapy is unclear...
  39. ncbi Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival
    Yun Shin Chun
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA
    J Gastrointest Surg 11:1498-504; discussion 1504-5. 2007
    ..The aim of this study was to compare the outcome of patients with CLM treated with preoperative chemotherapy followed by one- or two-stage hepatectomy...
  40. ncbi Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma
    Chandrajit P Raut
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg 246:52-60. 2007
    ..To better understand the impact of a microscopically positive margin (R1) on patterns of disease recurrence and survival after pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma...
  41. ncbi Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis
    Srinevas K Reddy
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Ann Surg Oncol 16:1809-19. 2009
    ..However, prospective randomized trials are needed to determine the optimal timing of chemotherapy...
  42. ncbi Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis
    Srinevas K Reddy
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Ann Surg Oncol 14:3481-91. 2007
    ..This multi-institutional retrospective study compared postoperative outcomes after simultaneous and staged colorectal and hepatic resections...
  43. ncbi Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation
    Jeannelyn S Estrella
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:268-77. 2012
    ..However, analysis of prognostic factors is limited for patients with PDAC treated with neoadjuvant chemoradiation and pancreaticoduodenectomy (PD)...
  44. ncbi Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma
    Ahmed O Kaseb
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 29:3892-9. 2011
    ..The study objective was to improve prognostic stratification of patients with HCC...
  45. ncbi Radiation treatment outcomes for unresectable hepatocellular carcinoma
    Heath D Skinner
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Acta Oncol 50:1191-8. 2011
    ..Data regarding the use of radiotherapy is limited in patients from populations without endemic viral hepatitis. We examine the outcomes for patients treated with radiotherapy in the modern era at a single institution...
  46. ncbi Risk factors for pancreatic cancer: case-control study
    Manal M Hassan
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Gastroenterol 102:2696-707. 2007
    ..We evaluated the independent effects of multiple risk factors for pancreatic cancer and determined whether the magnitude of cigarette smoking was modified by other risk factors in men and women...
  47. ncbi Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer: a case-control study
    Manal M Hassan
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:2547-56. 2007
    ..The associations between passive smoking and the use of noncigarette tobacco products with pancreatic cancer are not clear...
  48. ncbi Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment
    Jean Nicolas Vauthey
    Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Coll Surg 204:1016-27; discussion 1027-8. 2007
    ....
  49. ncbi Improved survival after resection of liver and lung colorectal metastases compared with liver-only metastases: a study of 112 patients with limited lung metastatic disease
    Antoine Brouquet
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4008, USA
    J Am Coll Surg 213:62-9; discussion 69-71. 2011
    ..Lung metastases are considered a poor prognostic factor in patients with resectable colorectal liver metastases...
  50. ncbi Resection of hepatic colorectal metastases involving the caudate lobe: perioperative outcome and survival
    Eddie K Abdalla
    Department of Surgical Oncology Unit 444, University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    J Gastrointest Surg 11:66-72. 2007
    ..To examine clinical features and outcome of patients who underwent hepatic resection for colorectal liver metastases (LM) involving the caudate lobe...
  51. ncbi Outcome after curative resection for locally recurrent rectal cancer
    Isabelle Bedrosian
    Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 444, Houston, Texas 77030, USA
    Dis Colon Rectum 49:175-82. 2006
    ..Preoperative carcinoembryonic antigen and an R0 resection margin were the only significant predictors of overall survival. p53, bcl-2, and ki-67 did not impact survival outcomes...
  52. ncbi Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy
    Yoji Kishi
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Ann Surg Oncol 16:614-22. 2009
    ..Whether neutrophil-to-lymphocyte ratio (NLR) predicts survival of patients with colorectal liver metastases (CLM) treated with systemic chemotherapy remains unclear...
  53. ncbi Chemotherapy prior to hepatic resection for colorectal liver metastases: helpful until harmful?
    Eddie K Abdalla
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Dig Surg 25:421-9. 2008
    ..Controversy exists regarding potential hepatotoxicity of therapy delivered before liver resection...
  54. ncbi Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases
    Daria Zorzi
    Departments of Surgical Oncology and Interventional Radiology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX, 77030, USA
    Ann Surg Oncol 15:2765-72. 2008
    ....
  55. ncbi Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 426, Houston, TX 77030, USA
    J Clin Oncol 26:3487-95. 2008
    ..We conducted a phase II trial of preoperative gemcitabine and cisplatin chemotherapy in addition to chemoradiation (Gem-Cis-XRT) and pancreaticoduodenectomy (PD) for patients with stage I/II pancreatic adenocarcinoma...
  56. ncbi Preoperative portal vein embolization for extended hepatectomy
    Alan W Hemming
    Department of Surgery, Center for Hepatobiliary Disease, University of Florida, Gainesville, FL 32610, USA
    Ann Surg 237:686-91; discussion 691-3. 2003
    ..To examine the authors' experience with preoperative ipsilateral portal vein embolization (PVE) and assess its role in extended hepatectomy...
  57. ncbi Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases
    Dan G Blazer
    Department of Surgical Oncology, Gastrointestinal Medical Oncology, and Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 26:5344-51. 2008
    ..The secondary goal of the study was to identify the clinical predictors of pathologic response...
  58. ncbi Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection
    Ryan M Thomas
    Department of Surgical Oncology, Unit 444, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Gastrointest Surg 16:1696-704. 2012
    ..Resection of certain recurrent malignancies can prolong survival, but resection of recurrent pancreatic ductal adenocarcinoma is typically contraindicated because of poor outcomes...
  59. ncbi Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome
    Deyali Chatterjee
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:3182-90. 2012
    ..Several grading schemes for the extent of residual tumor in posttreatment pancreaticoduodenectomy (PD) specimens have been proposed. However, the prognostic significance of these grading schemes is unknown...
  60. ncbi Repeat hepatectomy for recurrent colorectal liver metastases is associated with a high survival rate
    Andreas Andreou
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
    HPB (Oxford) 13:774-82. 2011
    ..The outcome after a repeat hepatectomy for recurrent colorectal liver metastases (CLM) is not well defined. The present study examined the morbidity, mortality and long-term survivals after a repeat hepatectomy for recurrent CLM...
  61. ncbi Concurrent capecitabine and upper abdominal radiation therapy is well tolerated
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Radiat Oncol 1:41. 2006
    ..Therefore, capecitabine and concurrent radiotherapy to the upper abdomen appears to be well tolerated. Capecitabine may serve as an alternative to bolus or infusional 5-FU during chemoradiation for upper gastrointestinal malignancies...
  62. ncbi Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone
    Yerko Borghero
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 97, Houston, TX 77030, USA
    Ann Surg Oncol 15:3147-56. 2008
    ....
  63. ncbi Is embolization of segment 4 portal veins before extended right hepatectomy justified?
    Yoji Kishi
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Surgery 144:744-51. 2008
    ..However, whether segment 4 (S4) portal veins should be embolized is controversial. The effect of S4 PVE on the volume gain of segments 2 and 3 (S2+3) was examined...
  64. ncbi Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:2549-55. 2010
    ..We sought to explore the relationship between oxaliplatin induced hepatic sinusoidal injury, increases in spleen size, and the subsequent development of thrombocytopenia...
  65. ncbi Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival
    Martin Palavecino
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
    Surgery 145:399-405. 2009
    ..Perioperative outcome and survival after major hepatic resection for HCC, with and without PVE, were investigated...
  66. ncbi Long-term survival after surgical management of neuroendocrine hepatic metastases
    Evan S Glazer
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    HPB (Oxford) 12:427-33. 2010
    ..Surgical cytoreduction and endocrine blockade are important options for care for neuroendocrine liver metastases. We investigated the long-term survival of patients surgically treated for hepatic neuroendocrine metastases...
  67. ncbi The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States
    Manal M Hassan
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 426, Houston, TX 77030, USA
    J Hepatol 50:334-41. 2009
    ..The study aimed at addressing the connection between positive family history of liver cancer and hepatocellular carcinoma (HCC) development in the USA...
  68. ncbi Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma
    Christopher H Crane
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:517-24. 2003
    ..This article investigates the relationship between objective tumor response and sphincter preservation in low rectal carcinoma patients...
  69. ncbi Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration
    Mark J Truty
    Department of Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Coll Surg 215:41-51; discussion 51-2. 2012
    ..We hypothesized that accurate radiographic restaging, multimodality treatment, and advanced surgical technique can offer patients deemed unresectable at previous exploration the possibility for curative salvage pancreatectomy...
  70. ncbi Comparison of two methods of future liver remnant volume measurement
    Yun Shin Chun
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 325, Houston, TX 77030, USA
    J Gastrointest Surg 12:123-8. 2008
    ..The purpose of this study was to compare FLR volumes standardized to BW versus BSA and to assess their utility in predicting postoperative hepatic dysfunction after hepatic resection...
  71. ncbi Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma
    Manal M Hassan
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:1938-46. 2010
    ..This objective of the current study was to determine the association between HCC risk and diabetes duration and type of diabetes treatment...
  72. ncbi The management of solitary colorectal liver metastases
    Antoine Brouquet
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, United States
    Surgeon 9:265-72. 2011
    ....
  73. ncbi Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study
    Manal M Hassan
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Cancer 123:1883-91. 2008
    ..Controlling for smoking exposure might be a prudent approach to the prevention of HCC, especially in patients with chronic viral hepatitis infections...
  74. ncbi Two-surgeon technique of parenchymal transection contributes to reduced transfusion rate in patients undergoing major hepatectomy: analysis of 1,557 consecutive liver resections
    Martin Palavecino
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Surgery 147:40-8. 2010
    ..Data on factors affecting blood transfusions in large series of liver resection are limited. The aim of this study was to evaluate factors predictive of blood transfusion in hepatectomies performed at a tertiary referral center...
  75. ncbi Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis
    Timothy M Pawlik
    Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD, USA
    Ann Surg Oncol 14:2807-16. 2007
    ..The role of hepatic resection for metastatic squamous cell carcinoma (SCC) remains unknown. The current study evaluates the role of hepatic resection in patients with metastatic SCC to the liver...
  76. ncbi Subtotal hepatectomy following neoadjuvant chemotherapy for a previously unresectable hepatocellular carcinoma
    Daria Zorzi
    Department of Surgical Oncology, Unit 444, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, 77030-4009, USA
    J Hepatobiliary Pancreat Surg 13:347-50. 2006
    ..This case illustrates that the combination of innovative neoadjuvant chemotherapy and well-planned surgical approaches may benefit a small number of patients previously deemed unresectable...
  77. ncbi Liver resection in the treatment of hepatocellular carcinoma
    Dario Ribero
    Department of Surgical Oncology, Unit 444, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Expert Rev Anticancer Ther 6:567-79. 2006
    ..An overview of the most common staging systems, which are useful in predicting prognosis after liver resection for hepatocellular carcinoma, is given...
  78. ncbi Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases
    Eddie K Abdalla
    Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    Ann Surg 239:818-25; discussion 825-7. 2004
    ..RFA alone or in combination with resection for unresectable patients does not provide survival comparable to resection, and provides survival only slightly superior to nonsurgical treatment...
  79. ncbi A marking technique for intraoperative localization of small liver metastases before systemic chemotherapy
    Stephane Zalinski
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg Oncol 16:1208-11. 2009
    ..This technique facilitates the resection of small lesions likely to disappear after preoperative chemotherapy...
  80. ncbi Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases
    Yun Shin Chun
    Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Lancet Oncol 10:278-86. 2009
    ....
  81. ncbi A role for curative surgery in the treatment of selected patients with metastatic breast cancer
    S Eva Singletary
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 444, Houston, Texas 77030 4095, USA
    Oncologist 8:241-51. 2003
    ..The addition of chest x-rays as part of routine follow-up should be considered as a cost-effective approach for early assessment of metastases to the lung or sternum that may be appropriate for surgical excision...
  82. ncbi Debunking dogma: surgery for four or more colorectal liver metastases is justified
    Timothy M Pawlik
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Gastrointest Surg 10:240-8. 2006
    ..Certain clinicopathologic factors, including lack of response to neoadjuvant chemotherapy, were associated with a worse prognosis...
  83. ncbi Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 16:836-47. 2009
    ..We evaluated long-term survival and patterns of recurrence in patients treated for PC with contemporary staging and multimodality therapy...
  84. ncbi Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients
    Mark Bonnen
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 60:1098-105. 2004
    ..This strategy should be prospectively studied in a group of patients with low rectal cancer who have no clinical evidence of tumor after chemoradiation...
  85. ncbi Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases
    Daria Zorzi
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
    J Gastrointest Surg 10:86-94. 2006
    ..AR is not superior to WR in terms of tumor clearance, pattern of recurrence, or survival. WR should remain an integral component of the surgical treatment of CLM...
  86. ncbi Predicting the node-negative mesorectum after preoperative chemoradiation for locally advanced rectal carcinoma
    Isabelle Bedrosian
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Gastrointest Surg 8:56-62; discussion 62-3. 2004
    ..Despite a substantial reduction in tumor volume with neoadjuvant CRT, local excision should be recommended with caution in patients with locally advanced rectal cancer...
  87. ncbi Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease
    Timothy M Pawlik
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston 77030, USA
    Ann Surg Oncol 13:712-20. 2006
    ..Resection should be performed as part of a multidisciplinary approach, because recurrence is common...
  88. ncbi Solitary colorectal liver metastasis: resection determines outcome
    Thomas A Aloia
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77230-1402, USA
    Arch Surg 141:460-6; discussion 466-7. 2006
    ..Every method should be considered to achieve resection of solitary colorectal liver metastasis, including referral to a specialty center, extended hepatectomy, and chemotherapy...
  89. ncbi Pancreaticoduodenectomy with vascular resection: margin status and survival duration
    Jennifer F Tseng
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    J Gastrointest Surg 8:935-49; discussion 949-50. 2004
    ....
  90. ncbi Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases
    Timothy M Pawlik
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg 241:715-22, discussion 722-4. 2005
    ..A predicted margin of <1 cm after resection of hepatic colorectal metastases should not be used as an exclusion criterion for resection...
  91. ncbi Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival
    Sanjay Gupta
    Section og Interventional Radiology, Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 104:1590-602. 2005
    ....
  92. ncbi Staging systems: Is there a surgical staging and a medical one? A surgeon's perspective
    Carlo M Contreras
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, PO Box 301402, 1515 Holcombe Boulevard Unit 444, Houston, TX 77230 1402, USA
    J Hepatobiliary Pancreat Sci 17:438-9. 2010
    ....
  93. ncbi Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer
    Courtney L Scaife
    Departments of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg Oncol 10:348-54. 2003
    ..The high rate of disease recurrence in our patients indicates that novel combinations of regional and systemic therapies are needed to improve patient outcomes...
  94. ncbi One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
    James C Yao
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 26:3063-72. 2008
    ..Clinicians need to be become familiar with the natural history and patterns of disease progression, which are characteristic of these tumors...
  95. ncbi Surgical resection of high-risk hepatocellular carcinoma: patient selection, preoperative considerations, and operative technique
    Mark J Truty
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 17:1219-25. 2010
    ..This review focuses on the surgical treatment of these high-risk patients, focusing on our own institution's approach and methods as well as reviewing the literature pertinent to the support of our current practice...
  96. ncbi Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States
    Manal M Hassan
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Hepatology 49:1563-70. 2009
    ..Experimental investigations are necessary for thorough assessment of the relationship between thyroid disorders and HCC...
  97. ncbi Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases
    Matteo Donadon
    The University of Texas, MD, Anderson Cancer Center, Department of Surgical Oncology, Unit 444, 1515 Holcombe Boulevard, Houston, Texas 77030, United States
    World J Gastroenterol 12:6556-8. 2006
    ....
  98. ncbi Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver
    Timothy M Pawlik
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
    Arch Surg 141:537-43; discussion 543-4. 2006
    ..Patients with sarcoma liver metastasis should be evaluated by a multidisciplinary team, as recurrence is common and adjuvant therapy may prolong survival...
  99. ncbi Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma
    Timothy M Pawlik
    Department of Surgery, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
    Arch Surg 140:450-7; discussion 457-8. 2005
    ..Clinical predictors should not be used to exclude patients from surgical resection because these factors do not reliably predict outcome...
  100. ncbi Preoperative predictors of survival after resection of small hepatocellular carcinomas
    Jeffrey D Wayne
    International Cooperative Study Group on Hepatocellular Carcinoma: Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg 235:722-30; discussion 730-1. 2002
    ..In these patients, transplantation and/or ablation should be considered as possible alternative therapies...
  101. ncbi Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma
    Timothy M Pawlik
    Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77230, USA
    Liver Transpl 11:1086-92. 2005
    ....